Dopamine synthesis, uptake, metabolism, and receptors: Relevance to gene therapy of Parkinson's disease

Experimental Neurology

Volumn 144, Issue 1, 1997, Pages 4-9

  Elsworth, John D ^a   Roth, Robert H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR;

ARTICLE; DOPAMINE METABOLISM; DOPAMINE UPTAKE; GENE THERAPY; HUMAN; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0031104698     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1996.6379     Document Type: Article

References (44)

1. 1. AMARA, S., AND M. KUHAR. 1993. Neurotransmitter transporters: Recent progress. Annu. Rev. Neurosci. 16: 73-93.
2. 2. AXELROD, J., AND R. WEINSHILBOUM. 1972. Catecholamines. N. Engl. J. Med. 287: 237-242.
3. 3. BANNON, M., J. GRANNEMAN, AND G. KAPATOS. 1995. The dopamine transporter: Potential involvement in neuropsychiatric disorders. Pages 179-188 in F. Bloom and D. Kupfer, Eds., Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York.
4. 4. BARBEAU, A. 1961. Biochemistry of Parkinson's disease. Proc. 7th Int. Congr. Neurol. 2: 925.
5. 5. BIRKMAYER, W., AND O. HORNYKIEWICZ. 1961. Der L-3,4-Dioxyphenylalanin (=DOPA)-Effekt bei der Parkinson-Akinese. Wien. Klin. Wochenschr. 73: 787-788.
6. 6. BLASCHKO, H. 1957. Metabolism and storage of biogenic amines. Experientia 13: 9-12.
7. 7. CARLSSON, A. 1959. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 11: 490-493.
8. 8. COOPER, J., F. BLOOM, AND R. ROTH. 1996. The Biochemical Basis of Neuropsychopharmacology. Oxford Univ. Press, New York.
9. 9. EHRINGER, H., AND O. HORNYKIEWICZ. 1960. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38: 1236-1239.
10. 10. ELSWORTH, J., AND R. ROTH. 1996. Dopamine autoreceptor pharmacology and function: Recent insights. Pages 223-265 in K. Neve and R. Neve, Eds., The Dopamine Receptors. Humana Press, Totowa, NJ.
11. 11. ELSWORTH, J. D., AND R. H. ROTH. 1993. Deprenyl: Pharmacological aspects of its clinical effects. Biogenic Amines 9: 381-394.
12. 12. FOLDES, A., AND J. L. MEEK. 1973. Rat brain phenolsulfotransferase-partial purification and some properties. Biochim. Biophys. Acta 327: 365-374.
13. 13. FERNSTROM, J. 1983. Role of precursor availability in control of monoamine biosynthesis in brain. Physiol. Rev. 63: 484-546.
14. 14. GIROS, B., AND M. CARON. 1993. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 14: 43-49.
15. 15. GONZALEZ, A., D. WALTHER, A. PAZOS, AND G. UHL. 1994. Synaptic vesicular monoamine transporter expression: distribution and pharmacological profile. Mol. Brain Res. 22: 219-226.
16. 16. GRACE, A., AND B. BUNNEY. 1995. Electrophysiological properties of midbrain dopamine neurons. Pages 163-177 in F. Bloom and D. Kupfer, Eds., Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York.
17. 17. GRAYBIEL, A., E. HIRSCH, AND Y. AGID. 1990. The nigrostriatal system in Parkinson's disease. Adv. Neurol. 53: 17-29.
18. 18. HENRY, J., D. BOTTON, C. SAGNE, M. ISAMBERT, C. DESNOS, V. BLANCHARD, R. RAISMAN-VOZARI, E. KREJCI, J. MASSOULIE, AND B. GASNIER. 1994. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. J. Exp. Biol. 196: 251-262.
19. 19. HITRI, A., Y. HURD, R. WYATT, AND S. DEUTSCH. 1994. Molecular, functional and biochemical characteristics of the dopamine transporter: Regional differences and clinical relevance. Clin. Neuropharmacol. 17: 1-22.
20. 20. HORNYKIEWICZ, O. 1993. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: Possible neurochemical mechanisms. Adv. Neurol. 60: 140-147.
21. 21. HURD, Y. L., Z. B. PRISTUPA, M. M. HERMAN, H. B. NIZNIK, AND J. E. KLEINMAN. 1994. The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbic-and motor-related subpopulations of human mesencephalic neurons. Neuroscience 63: 357-362.
22. 22. ICARD-LIEPKALNS, C., S. BERRARD, N. FAUCON-BIGUET, B. LEBOUR-DELLES, P. RAVASSARD, J. ROBERT, AND J. MALLET. 1993. Tyrosine hydroxylase regulation in neurotransmission and neuroplasticity. J. Physiol. 87: 153-157.
23. 23. KEEFE, K., AND C. GERFEN. 1995. D1-D2 dopamine receptor synergy in striatum: Effects of intrastriatal infusions of dopamine agonists and antagonists on immediate early gene expression. Neuroscience 66: 903-913.
24. 24. KELLY, R. 1993. Storage and release of neurotransmitters. Neuron 10 (Suppl): 43-53.
25. 25. KOPIN, I. 1985. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol. Rev. 37: 333-364.
26. 26. MEADOR-WOODRUFF, J. H., S. P. DAMASK, AND S. J. J. WATSON. 1994. Differential expression of autoreceptors in the ascending dopamine systems of the human brain. Proc. Natl. Acad. Sci. USA 91: 8297-8301.
27. 27. MILNER, J., AND R. WURTMAN. 1986. Catecholamine synthesis: Physiological coupling to precursor supply. Biochem. Pharmacol. 35: 875-881.
28. 28. MISU, Y., AND Y. GOSHIMA. 1993. Is L-dopa an endogenous neurotransmitter? Trends Pharmacol. Sci. 14: 119-123.
29. 29. MIYAMOTO, J., E. UEZU, AND S. TERASHIMA. 1991. Active transport pumps of HVA and DOPAC in dopaminergic nerve terminals. Physiol. Behav. 49: 141-147.
30. 30. MOGI, M., M. HARADA, K. KIUCHI, K. KOJIMA, T. KONDO, H. NARABAYASHI, D. RAUSH, P. RIEDERER, K. JELLINGER, AND T. NAGATSU. 1988. Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in Parkinson's disease. J. Neural Transm. 72: 77-82.
31. 31. NAGATSU, T. 1993. Biochemical aspects of Parkinson's disease. Adv. Neurol. 60: 165-174.
32. 32. NAOI, M., P. DOSTERT, M. YOSHIDA, AND T. NAGATSU. 1993. N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins. Adv. Neurol. 60: 212-217.
33. 33. NAUDON, L., I. LEROUX-NICOLLET, AND J. COSTENTIN. 1992. Kainic acid lesion of the striatum increases dopamine release but reduces 3-methoxytyramine level. Brain Res. 572: 247-249.
34. 34. PETER, D., Y. LIU, N. BRECHA, AND R. EDWARDS. 1995. The transport of neurotransmitters into synaptic vesicles. Prog. Brain Res. 105: 273-281.
35. 35. ROBERTSON, H. 1992. Dopamine receptor interactions: Some implications for the treatment of Parkinson's disease. Trends Neurosci. 15: 201-206.
36. 36. ROTH, J. A., J. RIVETT, AND K. RENSKERS. 1996. Pages 74-85 in M. Sandler and E. Usdin, Eds., Phenolsulfotransfersase in Mental Health Research. Macmillan & Co., London.
37. 37. ROTH, R. H., AND J. D. ELSWORTH. 1995. Biochemical pharmacology of midbrain dopamine neurons. Pages 227-244 in F. Bloom and D. Kupfer, Eds., Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York.
38. 38. SANDLER, M. 1972. Catecholamine synthesis and metabolism in man: Clinical implications (with special reference to parkinsonism). Pages 845-899 in H. Blaschko and E. Muscholl, Eds., Handbuch der Experimentellen Pharmakologie. Catecholamines, Vol. 33. Springer-Verlag, Berlin.
39. 39. SEEMAN, P., AND H. VAN TOL. 1994. Dopamine receptor pharmacology. Trends Pharmacol Sci. 15: 264-270.
40. 40. SOURKES, T. L., M. H. WISEMAN-DISTLER, J. F. MORAN, G. F. MURPHY, AND S. S. CYR. 1964. Comparative metabolism of D-and L-3,4-dihydroxyphenylalanine in normal and pryridoxine-deficient rats. Biochem. J. 93: 469-474.
41. 41. STRANGE, P. 1993. New insights into dopamine receptors in the central nervous system. Neurochem. Int. 22: 223-236.
42. 42. TIPTON, K. F., AND T. P. SINGER. 1993. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61: 1191-1206.
43. 43. YOUDIM, M., D. BEN-SHACHAR, AND P. RIEDERER. 1994. The enigma of neuromelanin in Parkinson's disease substantia nigra. J. Neural Transm. Suppl. 43: 113-122.
44. 44. ZIGMOND, M., E. ABERCROMBIE, T. BERGER, A. GRACE, AND E. STRICKER. 1990. Compensations after lesions of central dopaminergic neurons: Some clinical and basic implications. Trends Neurosci. 13: 290-296.